Latest news with #Syndax
Yahoo
6 days ago
- Business
- Yahoo
Citi ups Syndax target, opens ‘upside catalyst watch'
Citi analyst Yigal Nochomovitz raised the firm's price target on Syndax (SNDX) to $51 from $46 and keeps a Buy rating on the shares. The firm also added a positive 'upside catalyst watch' on Syndax ahead of the PDUFA deadline in relapsed or refractory NPM1-mutated acute myeloid leukemia of October 25. Q2 revenue of about $38M beat the firm's estimates by greater than 70% and Visible Alpha consensus by about 45%, driven by growth for Revuforj and Niktimvo, the analyst added. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on SNDX: Disclaimer & DisclosureReport an Issue Syndax price target raised to $56 from $43 at BTIG Syndax Pharmaceuticals Reports Strong Q2 2025 Growth Syndax Pharmaceuticals: Strong Performance and Growth Potential Justify Buy Rating Syndax reports Q2 EPS (83c), consensus ($1.01) Syndax options imply 9.0% move in share price post-earnings
Yahoo
13-06-2025
- Health
- Yahoo
Syndax reports publication of revumenib data from BEAT AML trial
Syndax (SNDX) Pharmaceuticals announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mutant NPM1 and KMT2A-rearranged acute myeloid leukemia patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th European Hematology Association Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. The publication and EHA presentation report updated results from the Phase 1b BEAT AML trial evaluating the safety and clinical activity of revumenib in combination with venetoclax/azacitidine in newly diagnosed older adults with mNPM1 or KMT2Ar AML. The trial is being conducted as part of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial. As of September 2024, 43 patients were enrolled and treated in BEAT AML across two dose levels of revumenib in combination with venetoclax and azacitidine. Overall, 79% of patients had mNPM1 AML and 21% had KMT2Ar AML. Revumenib was generally well tolerated at both dose levels in combination with venetoclax and azacitidine without a maximal tolerated dose identified. The most common overall non-hematologic treatment-emergent adverse events (TEAEs) of any grade were nausea (60%), constipation (53%), QTc prolongation (44%), hypokalemia (44%), and vomiting (42%). Overall Grade greater than or equal to3 non-hematologic AEs were rare and similar between both dose levels. In the intent-to-treat population, the observed rate of complete remission was 67%, composite complete remission was 81%, and the overall response rate was 88%. Among 37 patients with measurable residual disease response assessment, 100% were MRD negative by centralized flow cytometry testing. The median duration of CRc was 12.0 months. 23% of patients had proceeded to hematopoietic stem cell transplantation as of the February 2025 data cut off. In an early analysis of survival from this single-arm trial, the median overall survival observed was 15.5 months. Subset analysis showed a CRc rate of 77% and an observed median OS of 15.5 months in mNPM1 patients with intermediate risk by ELN 2024, and a CRc rate of 89% and observed median OS of 18.0 months in KMT2Ar patients. In contrast, historical data from newly diagnosed mNPM1 patients with intermediate risk treated with venetoclax and azacitidine show a CRc of 57% and median OS of 9.9 months.1 In newly diagnosed KMT2Ar AML patients treated with venetoclax and hypomethylating agent therapy, a CRc rate of 43% and median OS of 2.5 months was observed in a retrospective analysis. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SNDX: Disclaimer & DisclosureReport an Issue Syndax announces new data from AUGMENT-101 trial of Revuforj Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating Closing Bell Movers: slips 3% after results despite topping estimates Syndax exec buys $105.8K, director buys $91.1K in common stock Syndax Pharmaceuticals Appoints New Head of R&D Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET. A live webcast of the fireside chats will be available in the Investor section of the Company's website at where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Syndax ContactsSharon KlahreSyndax Pharmaceuticals, 781.684.9827 SNDX-G
Yahoo
08-05-2025
- Business
- Yahoo
Syndax Announces Participation in May Investor Conferences
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET. TD Cowen 6th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 28, 2025, at 10:30 a.m. ET. A live webcast of the fireside chats will be available in the Investor section of the Company's website at where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Syndax ContactsSharon KlahreSyndax Pharmaceuticals, 781.684.9827 SNDX-GError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Business
- Yahoo
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Syndax Contacts Sharon KlahreSyndax Pharmaceuticals, 781.684.9827 SNDX-GSign in to access your portfolio
